Driven by innovation and ESG practices, Health and Genesis' global competitiveness continues to rise.
Published Time:
2024-07-29
Recently, Joincare Pharmaceutical Group Industry Co., Ltd. ("Healthy Yuan", Stock Code: 600380.SH; JCARE) has been selected for inclusion in S&P Global's Sustainability Yearbook (China Edition) 2024 for its outstanding performance in Environmental, Social, and Governance (ESG) criteria. It stood out from over 1700 assessed Chinese companies across 60 industries, becoming one of five pharmaceutical companies selected. This highlights the company's achievements and influence in sustainable development.
Meanwhile, in recent years, with continuous government support, such as the release of "Implementation Plan for Full-Chain Support of Innovative Drug Development" and "Several Opinions on Building a Globally Competitive Open Environment for Technological Innovation", Healthy Yuan and Lizhu Group have accelerated their efforts, leading a new chapter in pharmaceutical innovation and sustainable development.
In the European and American markets, ESG has become an important standard for measuring a company's sustainability and investment value. A company's performance in environmental protection, social responsibility, and corporate governance not only affects its brand image and market valuation but also directly impacts its financing costs and investment attractiveness. With breakthroughs in domestic substitution in the field of inhalation preparations, innovation in high-barrier complex preparations, and good ESG practices, Healthy Yuan is accelerating its internationalization process in product R&D, market expansion, and investment and financing, continuously improving its "going global" and "bringing in" strategies to enhance its global market competitiveness and influence.
Actively Integrating into the Global Technological Innovation System
Encouraged by national policies, Healthy Yuan has actively responded and continuously increased investment in innovative drugs. According to the recent "Investor Relations Activity Record Table", the company is deeply implementing "Innovative Drugs + High-Barrier Complex Preparations" dual-engine driven strategy, focusing on unmet clinical needs and proactively deploying innovative drugs in multiple fields. Among them, the anti-influenza drug TG-1000 capsules have reached the key efficacy indicators preset in the clinical plan, and it is planned to communicate with the Center for Drug Evaluation (CDE) of the National Medical Products Administration regarding the listing application in the near future. This innovative achievement not only reflects Healthy Yuan's deep accumulation in the research and development of antiviral drugs but also provides strong support for the company's future market growth.
The release of the "Implementation Plan for Full-Chain Support of Innovative Drug Development" has provided a broader development space for innovative pharmaceutical companies such as Healthy Yuan and Lizhu Group. The plan emphasizes strengthening policy guarantees across the entire chain, making comprehensive use of policies related to price management, medical insurance payments, commercial insurance, drug allocation and use, investment and financing, optimizing the review and approval and medical institution assessment mechanisms, and jointly promoting the breakthrough development of innovative drugs. This policy dividend will strongly promote greater breakthroughs in innovative drug R&D and market expansion for Healthy Yuan and Lizhu Group.
At the same time, the "Several Opinions on Building a Globally Competitive Open Environment for Technological Innovation" also provides important support for the international development of Healthy Yuan and Lizhu Group. The opinion emphasizes adhering to the principle of promoting innovation through openness, improving the system and mechanism for technological opening to the outside world, and improving a global innovation system. Healthy Yuan and Lizhu Group actively integrate into the global innovation network and improve their internationalization level by establishing overseas R&D institutions and participating in international clinical trials. This open and cooperative attitude has not only brought Healthy Yuan advanced technologies and management experience but also injected new vitality into Healthy Yuan's innovative R&D.
Healthy Yuan has introduced license-in transactions to expand the company's respiratory disease product pipeline, further enriching Healthy Yuan's layout of R&D pipelines and product varieties in the respiratory field.
On March 20, Healthy Yuan Pharmaceutical and Bayer signed an exclusive license agreement for the development, commercialization, and production of a small molecule inhibitor in China. This is the first time Healthy Yuan has introduced an innovative drug pipeline in the respiratory field from a leading global multinational company. The small molecule compound involved is an innovative oral drug for chronic obstructive pulmonary disease (COPD) that effectively prevents the production of COPD inflammatory mediators by inhibiting prolyl endopeptidase (PREP) activity.
Respiratory diseases are one of the key therapeutic areas that the company focuses on. With this exclusive authorization from Bayer, Healthy Yuan has reached three important strategic collaborations in the respiratory field this year; including At the end of January 2024, the company successively announced two major strategic collaborations for drugs mainly used to treat asthma and chronic obstructive pulmonary disease and other respiratory diseases, including a strategic collaboration with Quansin Bio on the TSLP monoclonal antibody QX008N and a collaboration with Boan Bio on the exclusive rights in China for the long-acting anti-IL-4R monoclonal antibody BA2101 injection.
Practice ESG Wins Overseas Authority Rating Recognition
In the ESG field, Healthy Yuan and Lizhu Group have also performed outstandingly.
On July 16, Healthy Yuan was successfully selected for the "Sustainability Yearbook (China Edition) 2024" for the first time. S&P Global's corporate sustainability assessment is one of the largest-scale annual assessments of corporate sustainability practices globally. By quantifying and scoring companies' ESG management and performance, it comprehensively reflects companies' ESG management and information disclosure levels and is an important basis for global investor investment decisions and data analysis.
Lizhu Group, as Healthy Yuan's holding subsidiary, has also achieved remarkable achievements in ESG. Recently, Lizhu was also successfully selected for S&P Global's "Sustainability Yearbook (China Edition) 2024" and won the only "Industry Best Progress Enterprise" award in the Chinese pharmaceutical industry in 2023. It is worth mentioning that in February this year, Lizhu Group was also selected for S&P Global's "Sustainability Yearbook 2024" and won the only "Industry Mover" award in the global pharmaceutical industry in 2023.
Healthy Yuan and Lizhu Group's dual selection for the "Sustainability Yearbook (China Edition) 2024" signifies that both innovative pharmaceutical companies have made significant achievements in ESG practices.
Healthy Yuan has always adhered to its mission and vision of "For Health, For Tomorrow" and "Making Good Medicines with Care", and attaches great importance to corporate ESG management. By establishing a complete and rigorous ESG management framework, integrating ESG goals into individual performance appraisals, strengthening the ESG system, and continuously improving institutional management and implementing practical actions in key areas such as environmental protection, universal health, and corporate governance.
In 2023, Healthy Yuan also won numerous honors, including MSCI ESG AA rating, Wind ESG AA rating, and CSESG AAA rating. Lizhu Group has also achieved remarkable achievements in ESG, obtaining an MSCI ESG AAA rating, the first company in the Chinese pharmaceutical industry to receive the highest MSCI ESG rating. In addition, Lizhu has significantly improved its S&P ESG score and received Wind ESG AA rating and other honors. These achievements fully demonstrate Lizhu Group's outstanding capabilities and good practices in ESG governance.
ESG + Innovation Promotes Domestic and International Dual Circulation
Strengthening For HealthGen, ESG management is not only a reflection of its social responsibility but also a crucial pathway to enhancing its competitiveness. By continuously optimizing its environmental, social, and governance performance, HealthGen has established a positive corporate image in the European and American markets, attracting market access and gaining more attention and favor from overseas investors.
In recent years, HealthGen has adhered to two major development principles of "innovation" and "internationalization," deeply integrating the "bringing in" and "going out" strategies. While continuously improving its innovative drug pipeline R&D system, it is also actively developing innovative business cooperation models in the global market.
In 2023, HealthGen continued to promote the export of raw materials and the overseas expansion of key products, achieving continuous expansion of its overseas presence. Overseas revenue reached 2.584 billion yuan, accounting for 15.64% of the company's main business income.
Currently, HealthGen products have been exported to over 80 countries and regions in Asia, Europe, North America, and Africa, and it is actively promoting the international registration and certification of its products. Building on its existing advantages in raw material exports, HealthGen is actively promoting the overseas expansion planning and strategy for key pharmaceutical preparations.
According to publicly available information, HealthGen's chemical pharmaceutical products have been approved and registered overseas in 4 instances, with 14 new registrations submitted. Among them, Compound Ipratropium Bromide Solution has obtained registration approval in the Philippines; Levosalbutamol Hydrochloride Nebulizer Solution has obtained registration approval in Macao; and Ceftriaxone Sodium for Injection has received FDA approval.
In While "going out," HealthGen is also continuously deepening its "bringing in" strategy, including successfully introducing from overseas the new anti-influenza drug TG-1000, the innovative drug potassium-competitive acid blocker (P-CAB) in the digestive tract field, and oral drugs for chronic obstructive pulmonary disease (COPD).
In terms of innovative R&D, HealthGen continues to increase its R&D investment in high-barrier complex preparations and collaborates with many well-known domestic and international institutions to jointly promote new drug R&D and technological innovation. These efforts have enabled HealthGen to make significant breakthroughs in the field of complex preparations, enhancing the company's technological level and global competitiveness.
In addition to adopting "going out" and "bringing in" strategies for product markets and R&D, HealthGen is also actively participating in overseas capital market financing. By successfully issuing Global Depositary Receipts (GDRs) on the SIX Swiss Exchange, it has broadened its financing channels and attracted the attention of overseas professional investment institutions and industrial investors. This not only provides more financial support for the company but also helps to enhance its international reputation and influence.
This article is from: Zhengjing Finance